Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

120 results about "Chronic renal disease" patented technology

Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experiencing a reduced appetite.

Diagnosis and monitoring of chronic renal disease using ngal

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and / or maintaining a proper treatment regimen to slow or stop the progression of CRF.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1

Naphthyl sulfamide amino acid derivative, preparation method and medical application thereof

The invention discloses a naphthyl sulfamide amino acid derivative, a preparation method and medical application thereof. A naphthyl sulfamide amino acid derivative R3 substituent group represents a substituent group with an amino acid structure; the amino acid structure refers that the substituent group at least contains one carboxyl and one secondary amine or tertiary amine, and the substituentgroup is connected onto a mother nucleus through the secondary amine or the tertiary amine. The naphthyl sulfamide amino acid derivative provided by the invention can interfere with Keap1-Nrf2 combination and activate Nrf2, so that inflammatory injury is reduced, an inflammation microenvironment is improved, and the naphthyl sulfamide amino acid derivative has potential anti-inflammatory activity.The technician in the field knows that an Nrf2 activating agent can be used for inhibiting inflammatory reaction of diseases, so that the compound provided by the invention can be used for preparingan anti-inflammatory drug for treating diseases associated with inflammation, including chronic obstructive pulmonary diseases, Alzheimer diseases, Parkinson, atherosclerosis, chronic renal diseases,diabetes, intestinal inflammation, rheumatoid arthritis and the like.
Owner:CHINA PHARM UNIV

Traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method and use

The invention provides a traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method. The traditional Chinese medicine composition is prepared from the following raw material medicines by weight: 6-40 parts of rheum officinale, 10-95 parts of astragalus and 5-65 parts of salvia miltiorrhiza by a certain extraction and purification process into an injection, a freeze-dried powder injection or other oral preparations. Animal experiments confirm that, the traditional Chinese medicine composition can obviously improve the hemodynamic indexes of rats subjected to chronic glomerulonephritis, reduces serum IL-6, IL-8, and TNF (tumor necrosis factor)-alpha levels, significantly reduces serum creatinine and urea nitrogen and other indexes of rats subjected to hypertensive nephropathy, significantly reduces serum urea nitrogen and serum creatinine contents of rats subjected to the chronic renal failure, increases serum albumin content, and also can improve each hemodynamic index of rats subjected to the chronic renal failure; and pathological results show that the traditional Chinese medicine composition can improve and inhibit injures on kidney caused by the chronic renal diseases and chronic renal failure.
Owner:XIAN SHIJISHENGKANG PHARMA IND

Traditional Chinese medicine compound combination with function of curing chronic kidney diseases

The invention discloses a traditional Chinese medicine compound combination with a function of curing chronic kidney diseases. The traditional Chinese medicine compound combination is prepared by 20-60 parts of astragali radix, 15-45 parts of eucommia ulmoides, 10-30 parts of glossy privet fruit, 10-30 parts of cherokee rose fruit, 30-90 parts of caulis sinomenii, 30-90 parts of herba pyrrosiae, 15-45 parts of radix ranunculi ternati, 20-60 parts of rhizoma dioscoreae nipponicae, 15-45 parts of stiff silkworms and 5-15 parts of scorpion. The invention further discloses a preparation method of the traditional Chinese medicine compound combination and an application of the traditional Chinese medicine compound combination in curing the curing chronic kidney diseases. The traditional Chinese medicine compound combination is obtained through long-time clinical application and screening under the guidance of the traditional Chinese medicine theory according to the pathogenesis of the chronic kidney diseases. Clinical test results show that the traditional Chinese medicine compound combination can remarkably reduce proteinuria, protect the kidney function and control and stabilize the illness condition of a patient suffering from chronic nephritis, the effective rate is up to 91.7%, no remarkable adverse reaction occurs in the test process, the application is safe, and the traditional Chinese medicine compound combination is hopeful to be developed into a new drug for curing proteinuria of chronic nephritis.
Owner:JIANGSU PROVINCIAL HOSPITAL OF TCM

Chinese materia medica preparation for curing chronic kidney disease and preparation method of Chinese materia medica preparation

ActiveCN102579894ASignificant effectDelayed eGFRUrinary disorderPlant ingredientsSalvia miltiorrhizaChronic kidney disease stage 4
The invention discloses a Chinese materia medica preparation for curing a chronic kidney disease and a preparation method of the Chinese materia medica preparation. The Chinese materia medica preparation comprises astragalus root, pilose asiabell root, largehead atractylodes rhizome, indian buead, common yam rhizome, polygonum multiflorum, dodder, coix seed and salvia miltiorrhiza. The preparation method includes crushing raw ingredients, adding water to soak, boiling, decocting the raw ingredients, filtering, adding water into filter residues, repeating decoction, filtering, mixing two filter liquors, and obtaining the Chinese materia medica preparation. On the basis of the research of the field, the Chinese materia medica preparation is integrated with essence of the industry and is formed after being subjected to repeated demonstrations and optimizations. The Chinese materia medica preparation includes nine drugs such as the astragalus root, the pilose asiabell root, the dodder and the like, has a function of reinforcing spleen and kidney, has an obvious curative effect on the chronic kidney disease, particularly is good in effects of slowing down the decreasing of epidermal growth factor receptor (EGFR) of patients with chronic kidney disease stage 4 and the advancement of the chronic kidney disease, and is superior to an effective drug angiotensin-converting enzyme inhibitor (ACEI) internationally used.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Traditional Chinese medicine composition for treating chronic kidney diseases and chronic renal failure

The invention provides a traditional Chinese medicine composition for treating chronic kidney diseases and chronic renal failure. The traditional Chinese medicine composition is prepared from radix et rhizoma rhei preparata, Chinese peashrub roots, herba centellae, rhizoma curcumae, radix salviae miltiorrhizae, rhizoma smilacis glabrae, flos carthami, rhizoma polygoni cuspidati, herba pyrolae, lucid ganoderma, radix astragali and fructus aurantii. The radix et rhizoma rhei preparata has the effects of promoting blood circulation, detoxifying and eliminating turbidity, the Chinese peashrub roots has the effects of dispelling wind, detoxifying and reducring urinary protein, the herba centellae has the effects of dispelling wind, detoxifying and reducing creatinine, the rhizoma curcumae has the effects of breaking blood, promoting qi and resisting fibrosis, the radix salviae miltiorrhizae and the flos carthami have the effects of promoting blood circulation and removing blood stasis, the rhizoma smilacis glabrae has the effects of clearing heat, detoxifying and drying dampness, the rhizoma polygoni cuspidati has the effects of dispelling wind, detoxifying and reducing uric acid, the herba pyrolae has the effects of tonifying kidney and clearing away dieresis, the lucid ganoderma and the radix astragali have the effects of invigorating qi and strengthening health, and the fructus aurantii has the effects of soothing liver and regulating qi. The traditional Chinese medicine composition can effectively reduce proteinuria and hematuria of patients with chronic kidney diseases, relieve renal function progression of chronic renal failure, reduce serum creatinine, improve clinical symptoms of patients with chronic kidney diseases, especially chronic renal failure, and protect renal functions.
Owner:SHANGHAI SEVENTH PEOPLES HOSPITAL

Traditional Chinese medicine preparation for treating qi-yin deficiency syndrome of chronic kidney disease and preparation method of traditional Chinese medicine preparation

ActiveCN104288594AImprove viscera functionVisceral function protectionUrinary disorderGranular deliveryAbnormal renal functionYin deficiency
The invention discloses a traditional Chinese medicine preparation for treating qi-yin deficiency syndrome of a chronic kidney disease. The traditional Chinese medicine preparation comprises the following raw materials in parts by weight: 8-12 parts of dried radix rehmanniae, 8-12 parts of poria cocos, 8-12 parts of Chinese yam, 6-10 parts of dogwood, 8-12 parts of astragalus membranaceus, 8-12 parts of codonopsis pilosula, 8-12 parts of semen coicis, 8-12 parts of corn stigma, 12-18 parts of lalang grass rhizome, 8-12 parts of madder, 8-12 parts of herba cepbalanoplosis segeti, 8-12 parts of fructus rosae laevigatae and 8-12 parts of semen euryales. The preparation method comprises the following steps: during preparation, firstly, decocting various raw materials for three times according to the required ratio; mixing decoctions of three times; filtering and concentrating into thick paste of which the relative density is 1.2-1.3; and adding auxiliary materials, pelletizing and drying to prepare the traditional Chinese medicine preparation. The traditional Chinese medicine preparation has the efficacies of tonifying the kidneys and spleen, securing essence and clearing dampness, and tonifying qi and nourishing yin, and has a significant curative effect on hematuresis, proteinuria and abnormal renal function caused by chronic kidney diseases when the kidney function is protected.
Owner:湖北省中医院

Traditional Chinese medicine compound composition for delaying progress of chronic kidney diseases and clinical application of traditional Chinese medicine compound composition

The invention discloses a traditional Chinese medicine compound composition for delaying progress of chronic kidney diseases and clinical application of the traditional Chinese medicine compound composition. The traditional Chinese medicine compound composition which is a pure traditional Chinese medicine preparation comprises a plurality of traditional Chinese medicines including radix astragali, radix angelicae sinensis, rhizoma chuanxiong, radix achyranthis bidentatae, radix et rhizoma rhei preparata, serissa japonica, radix glycyrrhizae, hedyotis diffusa, herba centellae and caulis bambusae in taenia. The traditional Chinese medicine compound composition and the clinical application have the advantages that as shown by completed pharmacodynamical research and clinical research, the kidney fibrotic lesion degrees of experimental animals can be obviously improved by the preparation, the creatinine levels can be lowered, and kidney functions can be protected; the kidney pathological lesion degrees related to the chronic kidney diseases can be improved, and mechanisms related to curative effects are verified from the angle of molecular biology; as shown by clinical research, proteinuria and hematuria conditions related to the chronic kidney diseases can be reduced by the traditional Chinese medicine preparation, and deterioration of creatinine clearance rates (computed by the aid of Cockcraft-Gault formulas) of patients suffering from the chronic kidney diseases can be obviously controlled; the total treatment effective rate can reach 98% at least, expenditure required for treating the diseases can be reduced for the patients, the stable curative effects can be realized, and the traditional Chinese medicine compound composition is free of obvious toxic and side effects.
Owner:THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV

CKD (chronic kidney disease) animal model establishment

The invention relates to an application of adriamycin and adenine jointly used in preparing animal models used for screening medicine for treating a CKD. According to the invention, the application dose of adriamycin is 2.5-10 mg / Kg each time, and the application dose of adenine is 200 mg / Kg every day. The animal model more accords with the occurrence and development process of the human CKD, experimental results prompt that the model making time can be shortened when the two kinds of medicine are applied jointly, and kidney injury is more serious at the same time point.
Owner:樊均明

Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients

A new method of in vitro monitoring and assessing the need of a medication which interferes with the regulation of the parathyroid hormone level in a kidney patient subject to oxidative stress, notably hemodialysis patients. FIG. 1 shows the distribution of n-oxPTH concentrations in 340 hemodialysis patients (224 men and 116 women) with a median age of 66 years (IQR, 56 to 75 years), a median time since initiation of dialysis (dialysis vintage) of 266 days (IQR, 31 to 1209 days), and a median dialysis dose (kt / V) of 1.2 (IQR, 1.1 to 1.3). The cause of chronic kidney disease was nephrosclerosis in 113 cases (33%), diabetic nephropathy in 107 cases (31%), chronic glomerular nephritis in 29 cases (9%), polycystic kidney disease in 9 cases (3%) and other / unknown in 82 cases (24%). The median n-oxPTH concentration was 5.9 ng / L (IQR, 2.4 to 14.0 ng / L). n-oxPTH concentrations were not different in men and women (5.9 ng / L; IQR, 2.4 to 14.2 ng / L; n=224; vs. 5.5 ng / L; IQR, 2.4 to 14.0 ng / L; n=1 16; p=0.915).
Owner:IMMUNDIAGNOSTIK
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products